Currently, statins are the main therapy in dyslipidemia management but have been shown to increase the risk of new-onset diabetes, occurring in about 0.2% patients to 9-44% in different studies [34]; to counter this; previous investigations assessed the effect of the inhibitor of PCSK9 on the incidence of DM. This evidence concerns the gene PCSK9 and diabetes mellitus.